Blurbs

CymaBay Therapeutics (CBAY) Gets a Buy from H.C. Wainwright

In a report released today, Ed Arce from H.C. Wainwright maintained a Buy rating on CymaBay Therapeutics (CBAYResearch Report), with a price target of $10.00. The company’s shares closed yesterday at $3.61.

Arce covers the Healthcare sector, focusing on stocks such as Albireo Pharma, Mirum Pharmaceuticals, and Travere Therapeutics. According to TipRanks, Arce has an average return of 4.3% and a 35.81% success rate on recommended stocks.

Currently, the analyst consensus on CymaBay Therapeutics is a Strong Buy with an average price target of $9.00.

See Insiders’ Hot Stocks on TipRanks >>

The company has a one-year high of $4.30 and a one-year low of $1.67. Currently, CymaBay Therapeutics has an average volume of 357.7K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

CymaBay Therapeutics, Inc. is a clinical stage biopharmaceutical company, focused on developing and providing access to therapies for patients with liver and other chronic diseases with high unmet medical need. Its products include MBX-8025 and Arhalofenate, MBX-8025 aims to treat lipid and liver diseases while Arhalofenate intends to reduce gout flares and serum uric acid. The company was founded on October 5, 1988 and is headquartered in Newark, CA.

Read More on CBAY:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More